AU2013211346B2 - Anti-HBc quantitative detection method and uses thereof in monitoring and controlling disease progression of chronic hepatitis B patient and in predicting therapeutic effect - Google Patents

Anti-HBc quantitative detection method and uses thereof in monitoring and controlling disease progression of chronic hepatitis B patient and in predicting therapeutic effect Download PDF

Info

Publication number
AU2013211346B2
AU2013211346B2 AU2013211346A AU2013211346A AU2013211346B2 AU 2013211346 B2 AU2013211346 B2 AU 2013211346B2 AU 2013211346 A AU2013211346 A AU 2013211346A AU 2013211346 A AU2013211346 A AU 2013211346A AU 2013211346 B2 AU2013211346 B2 AU 2013211346B2
Authority
AU
Australia
Prior art keywords
hbc
patients
hepatitis
level
antibodies against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013211346A
Other languages
English (en)
Other versions
AU2013211346A1 (en
Inventor
Shengxiang Ge
Liuwei SONG
Zuxing WENG
Ningshao Xia
Feihai XU
Quan Yuan
Jun Zhang
Wenbin ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen University
Xiamen Innovax Biotech Co Ltd
Original Assignee
Xiamen University
Xiamen Innovax Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen University, Xiamen Innovax Biotech Co Ltd filed Critical Xiamen University
Publication of AU2013211346A1 publication Critical patent/AU2013211346A1/en
Application granted granted Critical
Publication of AU2013211346B2 publication Critical patent/AU2013211346B2/en
Priority to AU2018200744A priority Critical patent/AU2018200744B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5762—Hepatitis B core antigen
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/40—Fish
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Mycology (AREA)
AU2013211346A 2012-01-21 2013-01-17 Anti-HBc quantitative detection method and uses thereof in monitoring and controlling disease progression of chronic hepatitis B patient and in predicting therapeutic effect Active AU2013211346B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018200744A AU2018200744B2 (en) 2012-01-21 2018-01-31 Anti-HBc quantitative detection method and uses thereof in monitoring and controlling disease progression of chronic hepatitis B patient and in predicting therapeutic effect

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210019389.5A CN103217533B (zh) 2012-01-21 2012-01-21 Anti-HBc定量检测方法及其在监控慢性乙肝患者病情发展和预测治疗疗效中的用途
CN201210019389.5 2012-01-21
PCT/CN2013/070573 WO2013107355A1 (zh) 2012-01-21 2013-01-17 Anti-hbc 定量检测方法及其在监控慢性乙肝患者病情发展和预测治疗疗效中的用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018200744A Division AU2018200744B2 (en) 2012-01-21 2018-01-31 Anti-HBc quantitative detection method and uses thereof in monitoring and controlling disease progression of chronic hepatitis B patient and in predicting therapeutic effect

Publications (2)

Publication Number Publication Date
AU2013211346A1 AU2013211346A1 (en) 2014-08-28
AU2013211346B2 true AU2013211346B2 (en) 2017-11-30

Family

ID=48798632

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013211346A Active AU2013211346B2 (en) 2012-01-21 2013-01-17 Anti-HBc quantitative detection method and uses thereof in monitoring and controlling disease progression of chronic hepatitis B patient and in predicting therapeutic effect
AU2018200744A Active AU2018200744B2 (en) 2012-01-21 2018-01-31 Anti-HBc quantitative detection method and uses thereof in monitoring and controlling disease progression of chronic hepatitis B patient and in predicting therapeutic effect

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018200744A Active AU2018200744B2 (en) 2012-01-21 2018-01-31 Anti-HBc quantitative detection method and uses thereof in monitoring and controlling disease progression of chronic hepatitis B patient and in predicting therapeutic effect

Country Status (10)

Country Link
US (1) US9952217B2 (enExample)
EP (1) EP2805729B1 (enExample)
JP (2) JP6283319B2 (enExample)
KR (1) KR101739953B1 (enExample)
CN (1) CN103217533B (enExample)
AU (2) AU2013211346B2 (enExample)
BR (1) BR112014017877B1 (enExample)
CA (1) CA2861917C (enExample)
ES (1) ES2714274T3 (enExample)
WO (1) WO2013107355A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104338132A (zh) * 2013-07-26 2015-02-11 复旦大学 一种病毒免疫治疗药物复合物及其用途
CN106153923B (zh) * 2016-06-21 2017-12-05 北京大学第一医院 预测谷丙转氨酶小于二倍正常上限的慢性乙型病毒性肝炎患者肝脏炎症程度的系统
CN107044977A (zh) * 2016-06-30 2017-08-15 深圳市亚辉龙生物科技股份有限公司 一种酪氨酸磷酸酶抗体化学发光免疫检测试剂盒及其制备方法
CN109991411B (zh) * 2017-12-29 2023-01-20 上海索昕生物科技有限公司 一种检测待测样本中目标抗体的免疫测定方法及其应用
CN109900896A (zh) * 2019-03-12 2019-06-18 江苏伯纳德生物科技发展有限公司 一种酶联免疫法检测试剂盒及其制备方法
WO2022252745A1 (zh) * 2021-06-02 2022-12-08 重庆医科大学 一种免疫分子病毒颗粒检测试剂盒
CN117538520B (zh) * 2024-01-05 2024-04-02 山东康华生物医疗科技股份有限公司 一种HBc-IgM抗体检测试剂盒及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101545906A (zh) * 2008-03-25 2009-09-30 北京科美东雅生物技术有限公司 乙肝核心抗体磁微粒化学发光免疫分析测定试剂盒及其制备方法
CN101726596A (zh) * 2009-11-04 2010-06-09 无锡中德伯尔生物技术有限公司 检测乙肝五项的荧光微球免疫层析检测卡及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0382962A (ja) * 1989-08-28 1991-04-08 Tosoh Corp Ｂ型肝炎ウィルスＣｏｒｅ抗原に対する抗体の検出方法
JP4292670B2 (ja) * 2000-02-08 2009-07-08 東ソー株式会社 抗ＨＢｃ抗体の免疫測定法
US7713532B2 (en) 2002-09-06 2010-05-11 Advanced Life Science Institute, Inc. HBV precore protein capable of forming particles
CN1908666B (zh) * 2006-08-14 2010-05-12 武汉大学 一种检测乙肝核心抗体的双夹心法酶联免疫诊断试剂盒及应用
CN101377496A (zh) * 2008-04-16 2009-03-04 北京科美东雅生物技术有限公司 一种检测甲状腺过氧化物酶自身抗体的化学发光免疫分析测定试剂盒

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101545906A (zh) * 2008-03-25 2009-09-30 北京科美东雅生物技术有限公司 乙肝核心抗体磁微粒化学发光免疫分析测定试剂盒及其制备方法
CN101726596A (zh) * 2009-11-04 2010-06-09 无锡中德伯尔生物技术有限公司 检测乙肝五项的荧光微球免疫层析检测卡及其制备方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Brunetto et al (1993) Journal of Hepatology, 19(3):431-436 *
Chen et al (2006) Alimentary Pharmacology & Therapeutics, January, 23(1):85-90 *
Colloredo et al (1999) Journal of Viral Hepatitis, November, 6(6):429-434 *
Colloredo Mels et al (1993) Archives of Virology, Supplement 8:203-211 *
Galli et al (2008) Journal of Medical Virology, June, 80(6):974-979 *
Han et al (2011) Journal of Clinical Virology, December, 52(4):295-299 *
LI et al, (2010) Clinical and Vaccine Immunology, March, 17(3):464-469 *
Marinos et al (1994) Hepatology, February, 19(2):303-311 *
Rodella et al (2006) Journal of Clinical Virology, November, 37(3):206-212 *

Also Published As

Publication number Publication date
AU2018200744A1 (en) 2018-02-22
BR112014017877A2 (enExample) 2017-06-20
JP6283319B2 (ja) 2018-02-21
CA2861917C (en) 2021-03-23
CA2861917A1 (en) 2013-07-25
EP2805729A4 (en) 2015-11-11
AU2018200744B2 (en) 2019-08-08
BR112014017877B1 (pt) 2022-01-25
ES2714274T3 (es) 2019-05-28
US20150118674A1 (en) 2015-04-30
CN103217533A (zh) 2013-07-24
AU2013211346A1 (en) 2014-08-28
WO2013107355A1 (zh) 2013-07-25
EP2805729B1 (en) 2019-01-09
KR101739953B1 (ko) 2017-05-25
JP2018036268A (ja) 2018-03-08
BR112014017877A8 (pt) 2017-07-11
JP2015505371A (ja) 2015-02-19
US9952217B2 (en) 2018-04-24
EP2805729A1 (en) 2014-11-26
HK1198945A1 (en) 2015-06-19
KR20140117575A (ko) 2014-10-07
CN103217533B (zh) 2016-01-06

Similar Documents

Publication Publication Date Title
AU2018200744B2 (en) Anti-HBc quantitative detection method and uses thereof in monitoring and controlling disease progression of chronic hepatitis B patient and in predicting therapeutic effect
Coffin et al. New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection
Lee et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir
Liu et al. Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression
Cha et al. Performance evaluation of the OraQuick hepatitis C virus rapid antibody test
Krajden et al. The laboratory diagnosis of hepatitis B virus
Hosaka et al. HBcrAg is a predictor of post‐treatment recurrence of hepatocellular carcinoma during antiviral therapy
Shiels et al. Frequency and significance of concurrent hepatitis B surface antigen and antibody in acute and chronic hepatitis B
Huang et al. The role of hepatitis B virus core‐related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen‐negative patients
Coppola et al. Anti-HCV IgG avidity index in acute hepatitis C
Liu et al. Correlation between hepatitis B virus DNA levels and diagnostic tests for HBsAg, HBeAg, and PreS1-Ag in chronic hepatitis B.
Loggi et al. Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C
Riveiro-Barciela et al. How to interpret viral markers in the management of chronic hepatitis B infection
JP2015505371A5 (enExample)
Hwang et al. Baseline and on‐treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals
Kuo et al. Changing serum levels of quantitative hepatitis B surface antigen and hepatitis B virus DNA in hepatitis B virus surface antigen carriers: a follow‐up study of an elderly cohort
Assy et al. Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg (-) chronic hepatitis B patients from inactive chronic carriers
Kew et al. Comparison between polyclonal and first and second generation monoclonal radioimmunoassays in the detection of hepatitis B surface antigen in patients with hepatocellular carcinoma
HK1198945B (en) Anti-hbc quantitative detection in predicting therapeutic effect of chronic hepatitis b patient
Diawara et al. Profiling hepatitis B viral load: Treatment and epidemiological implications in a West African hospital
Liu et al. Comparison of two immunoassays for quantification of hepatitis B surface antigen in Chinese patients with concomitant hepatitis B surface antigen and hepatitis B surface antibodies
Saussakova et al. Management of Chronic Hepatitis B patients: HBsAg Kinetics
Liu et al. Steadily decline of HBV DNA load under NAs in lymphoma patients and higher level of qAnti-HBc predict HBV reactivation
Sunari et al. RELATIONSHIP OF ANTI-HBS ECLIA AND CLIA METHODS IN POSTVACCINATED PATIENTS IN SURABAYA, INDONESIA.
Xu et al. Evaluation of HBsAg and Anti‐HBs Coexistence: Authenticity and Contributing Factors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)